Contact
searchSearch
HMP Global
Login

Non-Small Cell Lung Cancer Specialty Channel

Non-Small Cell Lung Cancer
Specialty Channel
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
News
Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Improve Survival for EGFR-Mutated Non-Small Cell Lung Cancer
03/14/2025
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP...
03/14/2025
Oncology
News
First-Line Mobocertinib Fails to Improve Efficacy for EGFR-Mutated Advanced Non-Small Cell Lung Cancer
03/06/2025
Results from the phase 3 EXCLAIM-2 trial found that first-line mobocertinib failed to improve efficacy compared to platinum-based chemotherapy among patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.
Results from the phase 3 EXCLAIM-2 trial found that first-line mobocertinib failed to improve efficacy compared to platinum-based chemotherapy among patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.
Results from the phase 3...
03/06/2025
Oncology
News
Novel Engineered Toxin Body Targeting CTLA-4 Shows Potential Among Select Advanced Solid Tumors
03/06/2025
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial,...
03/06/2025
Oncology
News
First-Line Prolgolimab Plus Chemotherapy Improves Survival for Advanced Non-Squamous Non-Small Cell Lung Cancer
02/25/2025
Results from the phase 3 DOMAJOR study demonstrated that first-line prolgolimab plus chemotherapy improved survival outcomes among patients with advanced non-squamous non-small cell lung cancer.
Results from the phase 3 DOMAJOR study demonstrated that first-line prolgolimab plus chemotherapy improved survival outcomes among patients with advanced non-squamous non-small cell lung cancer.
Results from the phase 3 DOMAJOR...
02/25/2025
Oncology
News
Telisotuzumab Vedotin Plus Osimertinib Demonstrates Promise for Patients With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer With C-Met Overexpression
02/13/2025
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a...
02/13/2025
Oncology
News
Datopotamab Deruxtecan Shows Promise for Heavily Pretreated Patients With Advanced Non-Small Cell Lung Cancer With Actionable Mutations
01/30/2025
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the...
01/30/2025
Oncology
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Addition of Ramucirumab to Erlotinib Did Not Significantly Improve Overall Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
12/06/2024
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY...
12/06/2024
Oncology
News
Sunvozertinib Demonstrates Promise for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
12/06/2024
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results...
12/06/2024
Oncology
News
Cost-Effectiveness of Multi-Gene Panel Testing for Patients With Advanced Non-Small Cell Lung Cancer
12/05/2024
According to a real-world study, multi-gene panel testing was found to be cost-effective even at higher thresholds for patients with advanced non-small cell lung cancer.
According to a real-world study, multi-gene panel testing was found to be cost-effective even at higher thresholds for patients with advanced non-small cell lung cancer.
According to a real-world study,...
12/05/2024
Oncology

News

News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
News
Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Improve Survival for EGFR-Mutated Non-Small Cell Lung Cancer
03/14/2025
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP...
03/14/2025
Oncology
News
First-Line Mobocertinib Fails to Improve Efficacy for EGFR-Mutated Advanced Non-Small Cell Lung Cancer
03/06/2025
Results from the phase 3 EXCLAIM-2 trial found that first-line mobocertinib failed to improve efficacy compared to platinum-based chemotherapy among patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.
Results from the phase 3 EXCLAIM-2 trial found that first-line mobocertinib failed to improve efficacy compared to platinum-based chemotherapy among patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.
Results from the phase 3...
03/06/2025
Oncology
News
Novel Engineered Toxin Body Targeting CTLA-4 Shows Potential Among Select Advanced Solid Tumors
03/06/2025
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial,...
03/06/2025
Oncology
News
First-Line Prolgolimab Plus Chemotherapy Improves Survival for Advanced Non-Squamous Non-Small Cell Lung Cancer
02/25/2025
Results from the phase 3 DOMAJOR study demonstrated that first-line prolgolimab plus chemotherapy improved survival outcomes among patients with advanced non-squamous non-small cell lung cancer.
Results from the phase 3 DOMAJOR study demonstrated that first-line prolgolimab plus chemotherapy improved survival outcomes among patients with advanced non-squamous non-small cell lung cancer.
Results from the phase 3 DOMAJOR...
02/25/2025
Oncology
News
Telisotuzumab Vedotin Plus Osimertinib Demonstrates Promise for Patients With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer With C-Met Overexpression
02/13/2025
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a...
02/13/2025
Oncology
News
Datopotamab Deruxtecan Shows Promise for Heavily Pretreated Patients With Advanced Non-Small Cell Lung Cancer With Actionable Mutations
01/30/2025
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the...
01/30/2025
Oncology
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Addition of Ramucirumab to Erlotinib Did Not Significantly Improve Overall Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
12/06/2024
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY...
12/06/2024
Oncology
News
Sunvozertinib Demonstrates Promise for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
12/06/2024
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results...
12/06/2024
Oncology

Interactive Features

Quiz
Lorlatinib for Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer
06/13/2024
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year long-term follow-up results from the phase 3 CROWN study demonstrated that first-line loraltinib improved outcomes among patients with advanced ALK-positive non-small cell lung cancer.
True or False: Five-year...
06/13/2024
Oncology
Quiz
FDA Approves Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer
05/29/2024
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the phase 3 ALINA trial the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer. What is the recommended dose?
According to results from the...
05/29/2024
Oncology
Quiz
Amivantamab Plus Chemotherapy for Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer
04/04/2024
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the phase 3 PAPILLON trial, what percentage of patients remained on amivantamab plus chemotherapy at a follow-up of 18-months?
According to results from the...
04/04/2024
Oncology
Quiz
FDA Approves Osimertinib Plus Chemotherapy For EGFR-Mutated Advanced NSCLC
03/21/2024
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...
Based on results from the phase...
03/21/2024
Oncology
Quiz
Repotrectinib for ROS1 Fusion-Positive NSCLC
02/05/2024
02/05/2024
Oncology
Quiz
Sitravatinib Plus Nivolumab for Nonsquamous NSCLC After Progression on Checkpoint Inhibitors
05/16/2023
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with nonsquamous non-small cell lung cancer who had progressed after checkpoint inhibitor immunotherapy respond to combination sitravatinib and nivolumab?
How did patients with...
05/16/2023
Oncology
Quiz
Pembrolizumab Plus Chemotherapy Efficacy by PD-L1 Status in Metastatic NSCLC
04/17/2023
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score affect the improvement of long-term survival outcomes from pembrolizumab plus chemotherapy among patients with non-small cell lung cancer?
Did PD-L1 tumor proportion score...
04/17/2023
Oncology
Quiz
Treatment-Related Adverse Events With Nivolumab Plus Ipilimumab for NSCLC
04/13/2023
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus ipilimumab associated with a higher incidence of treatment-related adverse events than pembrolizumab monotherapy among patients with non-small cell lung cancer?
Was combination nivolumab plus...
04/13/2023
Oncology
Quiz
First-Line Immune Checkpoint Inhibitor Monotherapy for NSCLC
02/15/2023
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to first-line immune checkpoint inhibitor monotherapy compared to combination therapy for non-small cell lung cancer?
How did patients respond to...
02/15/2023
Oncology
Quiz
Quiz: Survival Outcomes With Pembrolizumab for Nonsquamous NSCLC
01/31/2023
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did pemetrexed and platinum-based chemotherapy plus pembrolizumab improve in patients with nonsquamous non-small cell lung cancer?
Which survival outcomes did...
01/31/2023
Oncology

Recent News

News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
News
Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Improve Survival for EGFR-Mutated Non-Small Cell Lung Cancer
03/14/2025
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP 15-19 ABC-lung trial demonstrated that atezolizumab plus bevacizumab and chemotherapy failed to improve survival outcomes for patients with EGFR-mutated non-small cell lung cancer that is resistant to TKIs.
Results from the phase 3 ETOP...
03/14/2025
Oncology
News
First-Line Mobocertinib Fails to Improve Efficacy for EGFR-Mutated Advanced Non-Small Cell Lung Cancer
03/06/2025
Results from the phase 3 EXCLAIM-2 trial found that first-line mobocertinib failed to improve efficacy compared to platinum-based chemotherapy among patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.
Results from the phase 3 EXCLAIM-2 trial found that first-line mobocertinib failed to improve efficacy compared to platinum-based chemotherapy among patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.
Results from the phase 3...
03/06/2025
Oncology
News
Novel Engineered Toxin Body Targeting CTLA-4 Shows Potential Among Select Advanced Solid Tumors
03/06/2025
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial,...
03/06/2025
Oncology
News
First-Line Prolgolimab Plus Chemotherapy Improves Survival for Advanced Non-Squamous Non-Small Cell Lung Cancer
02/25/2025
Results from the phase 3 DOMAJOR study demonstrated that first-line prolgolimab plus chemotherapy improved survival outcomes among patients with advanced non-squamous non-small cell lung cancer.
Results from the phase 3 DOMAJOR study demonstrated that first-line prolgolimab plus chemotherapy improved survival outcomes among patients with advanced non-squamous non-small cell lung cancer.
Results from the phase 3 DOMAJOR...
02/25/2025
Oncology
News
Telisotuzumab Vedotin Plus Osimertinib Demonstrates Promise for Patients With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer With C-Met Overexpression
02/13/2025
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a...
02/13/2025
Oncology
News
Datopotamab Deruxtecan Shows Promise for Heavily Pretreated Patients With Advanced Non-Small Cell Lung Cancer With Actionable Mutations
01/30/2025
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the phase 2 TROPION-Lung05 trial, datopotamab deruxtecan demonstrated promising antitumor activity among heavily pretreated patients with advanced or metastatic non-small cell lung cancer harboring actionable...
According to results from the...
01/30/2025
Oncology
News
Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
01/08/2025
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.
According to results from the...
01/08/2025
Oncology
News
Addition of Ramucirumab to Erlotinib Did Not Significantly Improve Overall Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
12/06/2024
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY trial demonstrated that the addition of ramucirumab to erlotinib did not significantly improve overall survival among patients with previously untreated EGFR-mutated metastatic non-small cell lung cancer.
Results from the phase 3 RELAY...
12/06/2024
Oncology
News
Sunvozertinib Demonstrates Promise for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
12/06/2024
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results demonstrated that sunvozertinib showed promise among patients with EGFR-mutated non-small cell lung cancer who developed resistance to EGFR TKIs.
Pooled analysis results...
12/06/2024
Oncology
News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases
04/01/2025
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a...
04/01/2025
Oncology
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Oncology
News
Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer
04/01/2025
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of...
04/01/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Oncology
FDA Approval
FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs
03/26/2025
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the...
03/26/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use